ERTIPROTAFIB

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C31H27BrO3S
Molecular Weight	559.513
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(C)C2=C(S1)C(Br)=C3C=CC=CC3=C2C4=CC(C)=C(O[C@H](CC5=CC=CC=C5)C(O)=O)C(C)=C4

InChI

InChIKey=FONCZICQWCUXEB-RUZDIDTESA-N

InChI=1S/C31H27BrO3S/c1-17-14-22(15-18(2)29(17)35-25(31(33)34)16-21-10-6-5-7-11-21)27-23-12-8-9-13-24(23)28(32)30-26(27)19(3)20(4)36-30/h5-15,25H,16H2,1-4H3,(H,33,34)/t25-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C31H27BrO3S
Molecular Weight	559.513
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17407812 | https://www.ncbi.nlm.nih.gov/pubmed/15475571 | https://adisinsight.springer.com/drugs/800016671

Ertiprotafib was originally developed as an inhibitor of PTP1B. Multiple targets of ertiprotafib, in addition to PTP1B inhibition, have been suggested including dual PPARalpha/PPARgamma agonism and IKK-beta inhibition. It normalized the plasma glucose and insulin levels in diabetic animal models and progressed to a phase II clinical trial for the treatment of Type 2 diabetes mellitus. Ertiprotafib development has been discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tyrosine-protein phosphatase non-receptor type 1 4 Target ID: P18031 Gene ID: 5770.0 Gene Symbol: PTPN1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24148325	Inhibitor 8504		0.87 µM [IC50]
Inhibitor of nuclear factor kappa-B kinase subunit beta 5 Target ID: O14920 Gene ID: 3551.0 Gene Symbol: IKBKB Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17407812	Inhibitor 8504		400.0 nM [IC50]

PubMed

Title	Date	PubMed
Discovery of novel PTP1B inhibitors via pharmacophore-oriented scaffold hopping from Ertiprotafib.	2013-12-01	24148325
2-Acyl-tetrahydroisoquinoline-3-carboxylic acids: lead compounds with triple actions, peroxisome proliferator-activated receptor α/γ agonist and protein-tyrosine phosphatase 1B inhibitory activities.	2011	21720040
PTP1B inhibitor Ertiprotafib is also a potent inhibitor of IkappaB kinase beta (IKK-beta).	2007-05-15	17407812
Effects of ertiprotafib on hepatic cytochrome P450 and peroxisomal enzymes in rats and dogs, and in rat and human primary hepatocytes.	2007-01	17178630
Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms.	2005-01	15475571

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:28:16 GMT 2025` Edited by `admin` on `Wed Apr 02 08:28:16 GMT 2025`
Record UNII	5TPM2EB426
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PTP-112

Preferred Name

English

ERTIPROTAFIB

Official Name

English

(2R)-2-[4-(9-Bromo-2,3-dimethylnaphtho[2,3-b]thiophen-4-yl)-2,6-dimethylphenoxy]-3-phenylpropionic acid

Systematic Name

English

ERTIPROTAFIB [USAN]

Common Name

English

ertiprotafib [INN]

Common Name

English

BENZENEPROPANOIC ACID, .ALPHA.-(4-(9-BROMO-2,3-DIMETHYLNAPHTHO(2,3-B)THIEN-4-YL)-2,6-DIMETHYLPHENOXY)-, (.ALPHA.R)-

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29711